🔗 Share this article Social Media Content Creators Fueling Unofficial Trade for Unapproved Weight-Loss Medication An underground market for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, based on new investigations. Experimental Drug Gaining Traction Online Retatrutide, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Followers are urged to contact these accounts directly for source information, while also obtaining promotional offers. Thriving Commerce on Messaging Platforms Additionally, a flourishing market exists on messaging services, where groups with thousands of participants share “before and after” images, injection guides and claims of rapid British shipping. Sellers promote the substance there before redirecting customers to other platforms for purchases. Understanding Retatrutide Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist patients lose up to a quarter of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the next Ozempic. Medical Professionals Express Concerns Nevertheless, physicians and chemists have warned that the sale of what is still an unapproved drug in the United Kingdom is worrisome and could result in users injecting substances of unknown origin. Some professionals stated the demand for the experimental drug could be connected to the increasing cost of approved weight loss products such as Mounjaro. Legal Position and Enforcement Selling retatrutide on TikTok or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012. Several influencers try to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still breach medicines, advertising, and customer laws, potentially leading to fines, prosecution or prison. Platform Reaction and Content Elimination Based on the social media company, the service has taken down problematic content and prohibited related hashtags and search suggestions. The company stated it was committed to keeping the service safe and investing in strengthening compliance measures. Digital Trading Operations Investigations also found communities with up to 9,000 members selling retatrutide using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, populated with photos of weight loss, positive reviews and detailed instructions for mixing or injecting at home. After moments of joining one community, a seller shared contact information, where most transactions take place. The vendor sent an instruction manual and promised delivery within two days. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a image of a supposed testing documentation. None inquired about body mass, medical conditions or past usage. Product Details and Pricing Within these communities, messages display dark colored packages with postal service labels, claiming to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.” Customers can choose between powder vials, mixed at home with sterile water, or ready-to-use pens usually priced at 160 pounds for 20 milligrams. When questioned how much time a injector should be used, vendors give conflicting answers varying between a several days to “depends on your body”. Service Moderation and Security Actions A representative for the messaging service said it actively monitored dangerous material on its platform including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”. Medical Professional Warnings “Individuals are injecting substances they cannot confirm. Although the science behind this drug is sound, these online products may not contain what they advertise,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service. A medical professional of Asda Online Doctor connected the increase in demand to current price rises for approved slimming medications such as Mounjaro. “With prices rising, individuals are using online platforms. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were made in was sterile,” she said. Her staff has already encountered individuals harmed by personal administration from unverified suppliers. “We understand the frustration, but buying from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These materials could be impure or improperly measured.” Manufacturer Statement A representative from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a company experimental substance not yet authorized … may expose users to potentially serious medical dangers”.